Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for March 12, 2019 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. SENS, a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its fourth quarter and full year 2018 financial results after market close on Tuesday, March 12, 2019.

Management will hold a conference call to review the company's fourth quarter and full year 2018 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events & Publications," and will be archived there for future reference. To listen to the conference call, please dial 866-519-2796 (US/Canada) or 786-789-4771 (International), passcode 117792, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® XL CGM System received CE mark for up to 180 days of continuous use and is available in Europe. For more information on Senseonics, please visit www.senseonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190220005865/en/